PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
877.13%
Growth of 877.13% versus flat Drug Manufacturers - Specialty & Generic revenue. Walter Schloss would verify growth quality.
-40.51%
Cost reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive advantage potential.
177.09%
Growth of 177.09% versus flat Drug Manufacturers - Specialty & Generic gross profit. Walter Schloss would verify quality.
-76.50%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
-76.75%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
83.85%
Marketing expense change of 83.85% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
102.73%
Other expenses change of 102.73% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify efficiency.
-65.72%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 6.51%. Seth Klarman would investigate advantages.
-66.24%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is 5.23%. Seth Klarman would investigate advantages.
-16.03%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-4.44%
D&A reduction while Drug Manufacturers - Specialty & Generic median is 0.37%. Seth Klarman would investigate efficiency.
84.96%
EBITDA growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
98.46%
Margin change of 98.46% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
-20.78%
Operating income decline while Drug Manufacturers - Specialty & Generic median is -7.34%. Seth Klarman would investigate causes.
87.64%
Margin change of 87.64% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
101.43%
Other expenses change of 101.43% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify control.
83.07%
Pre-tax income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
98.27%
Margin change of 98.27% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
99.36%
Tax expense change of 99.36% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify strategy.
83.07%
Net income growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
98.27%
Margin change of 98.27% versus flat Drug Manufacturers - Specialty & Generic. Walter Schloss would verify quality.
83.25%
EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
83.25%
Diluted EPS growth while Drug Manufacturers - Specialty & Generic declines. Peter Lynch would examine advantages.
0.59%
Share count change of 0.59% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.
0.59%
Diluted share change of 0.59% versus stable Drug Manufacturers - Specialty & Generic. Walter Schloss would verify approach.